Swedish Orphan Biovitrum AB (publ) operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Swedish Orphan Biovitrum AB (publ) with three other
pharmaceutical manufacturers in Europe:
Recipharm AB (publ)
sales of 3.39 billion Swedish Kronor [US$385.34 million]
of which 50%
(17.85 billion Russian Rubles [US$309.08 million]
based in France
(342.61 million Euro [US$370.39 million]
of which 60%
was Operating Segment - Europe).
Swedish Orphan Biovitrum AB (publ) reported sales of SEK 3.23 billion (US$366.98 million)
December of 2015.
increase of 23.8%
versus 2014, when the company's sales were SEK 2.61 billion.
Sales at Swedish Orphan Biovitrum AB (publ) have increased during each of the previous five years
(and since 2010, sales have increased a total of 69%).
Sales of Haemophilia:royalties saw an increase
that was more than double the company's growth rate: sales were up
211.3% in 2015, from
SEK 30.92 million to SEK 96.25 million.
Swedish Orphan Biovitrum AB (publ) also saw significant increases in sales in
Core Products/kineret (up 32.2% to SEK 805.36 million)
Core Products/orfadin (up 45.2% to SEK 795.71 million)